PARI Pharma GmbH – Product Pipeline Review – H2 2011

Date: December 1, 2011
Pages: 41
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PE9CB453948EN
Leaflet:

Download PDF Leaflet

PARI Pharma GmbH - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “PARI Pharma GmbH - Product Pipeline Review - H2 2011” provides data on the PARI Pharma GmbH’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, PARI Pharma GmbH’s corporate website, SEC filings, investor presentations and featured press releases, both from PARI Pharma GmbH and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • PARI Pharma GmbH - Brief PARI Pharma GmbH overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of PARI Pharma GmbH human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of PARI Pharma GmbH with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the PARI Pharma GmbH’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate PARI Pharma GmbH’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of PARI Pharma GmbH in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the PARI Pharma GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with PARI Pharma GmbH.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of PARI Pharma GmbH and identify potential opportunities in those areas.
PARI Pharma GmbH Snapshot
PARI Pharma GmbH Overview
Key Information
Key Facts
PARI Pharma GmbH – Research and Development Overview
Key Therapeutic Areas
PARI Pharma GmbH – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
PARI Pharma GmbH – Pipeline Products Glance
PARI Pharma GmbH – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
PARI Pharma GmbH Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
PARI Pharma GmbH – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
PARI Pharma GmbH – Drug Profiles
Aerosolized AAT
Anti-cholinergic drug
Anti-Inflammatory
Disodium cromoglycate (DSCG)
L-CsA
Levofloxacin vibrENT
Pari Tobramycin 100
PARI Pharma GmbH – Pipeline Analysis
PARI Pharma GmbH – Pipeline Products by Therapeutic Class
PARI Pharma GmbH - Pipeline Products By Target
PARI Pharma GmbH – Pipeline Products by Route of Administration
PARI Pharma GmbH – Pipeline Products by Molecule Type
PARI Pharma GmbH – Locations And Subsidiaries
Head Office
Company's Recent Developments
PARI Pharma GmbH, Recent Developments
May 20, 2009: PARI Pharma’s Nebulized DSCG Shows Results Similar To Inhaled Steroids In Asthma Studies Presented At ATS
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
Feb 11, 2010: PARI Pharma Initiates Enrollment In Phase IIb Study Of Liposomal Cyclosporine Against Bronchiolitis Obliterans
Nov 10, 2008: PARI Pharma Completes Successful Clinical Trials For Tobramycin 100 & Investigational eFlow For Cystic Fibrosis
May 07, 2009: PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin – eFlow Technology Program Forward
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
Financial Deals Landscape
PARI Pharma GmbH, Deals Summary
PARI Pharma GmbH, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Activaero Enters Into Agreement With PARI Pharma
PARI Aerosol Enters Into Agreement With Kamada
Licensing Agreements
Kamada Expands Licensing Agreement With Pari
Kamada Enters Into Licensing Agreement With PARI Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

PARI Pharma GmbH, Key Information
PARI Pharma GmbH, Key Facts
PARI Pharma GmbH – Pipeline by Therapy Area and Indication, H2 2011
PARI Pharma GmbH – Pipeline by Stage of Development, H2 2011
PARI Pharma GmbH – Monotherapy Products in Pipeline, H2 2011
PARI Pharma GmbH – Phase III, H2 2011
PARI Pharma GmbH - Phase II, H2 2011
PARI Pharma GmbH – Pre-Clinical, H2 2011
PARI Pharma GmbH - Pipeline By Therapeutic Class, H2 2011
PARI Pharma GmbH - Pipeline By Target, H2 2011
PARI Pharma GmbH – Pipeline By Route of Administration, H2 2011
PARI Pharma GmbH – Pipeline By Molecule Type, H2 2011
PARI Pharma GmbH, Deals Summary
Activaero Enters Into Agreement With PARI Pharma
PARI Aerosol Enters Into Agreement With Kamada
Kamada Expands Licensing Agreement With Pari
Kamada Enters Into Licensing Agreement With PARI Pharma

LIST OF FIGURES

PARI Pharma GmbH – Pipeline by Therapy Area and Indication, H2 2011
PARI Pharma GmbH – Pipeline by Stage of Development, H2 2011
PARI Pharma GmbH – Monotherapy Products in Pipeline, H2 2011
PARI Pharma GmbH – Pipeline By Therapeutic Class, H2 2011
PARI Pharma GmbH - Pipeline By Target, H2 2011
PARI Pharma GmbH – Pipeline By Molecule Type, H2 2011

Ask Your Question

PARI Pharma GmbH – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: